Zomacton 10 mg/ml pulver og solvens til injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zomacton 10 mg/ml pulver og solvens til injektionsvæske, opløsning

ferring lægemidler a/s - somatropin - pulver og solvens til injektionsvæske, opløsning - 10 mg/ml

Zomacton 4 mg pulver og solvens til injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zomacton 4 mg pulver og solvens til injektionsvæske, opløsning

ferring lægemidler a/s - somatropin - pulver og solvens til injektionsvæske, opløsning - 4 mg

Ngenla Den Europæiske Union - dansk - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Den Europæiske Union - dansk - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Locametz Den Europæiske Union - dansk - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.